Hypoxia-activated prodrugs and redox-responsive nanocarriers

Yun Zeng,1,* Jingwen Ma,2,* Yonghua Zhan,1 Xinyi Xu,1 Qi Zeng,1 Jimin Liang,1 Xueli Chen1 1Engineering Research Center of Molecular and Neuro Imaging of the Ministry of Education, School of Life Science and Technology, Xidian University, Xi’an 710071, Shaanxi Province, People’s...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zeng Y, Ma J, Zhan Y, Xu X, Zeng Q, Liang J, Chen X
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Anti-tumor drugs Hypoxia Nanoparticles Redox-sensitive Tumor therapy Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/13e8874b1c0449268f8e766f8935a70f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:13e8874b1c0449268f8e766f8935a70f
record_format	dspace
spelling	oai:doaj.org-article:13e8874b1c0449268f8e766f8935a70f2021-12-02T04:50:31ZHypoxia-activated prodrugs and redox-responsive nanocarriers1178-2013https://doaj.org/article/13e8874b1c0449268f8e766f8935a70f2018-10-01T00:00:00Zhttps://www.dovepress.com/hypoxia-activated-prodrugs-and-redox-responsive-nanocarriers-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Yun Zeng,1,* Jingwen Ma,2,* Yonghua Zhan,1 Xinyi Xu,1 Qi Zeng,1 Jimin Liang,1 Xueli Chen1 1Engineering Research Center of Molecular and Neuro Imaging of the Ministry of Education, School of Life Science and Technology, Xidian University, Xi’an 710071, Shaanxi Province, People’s Republic of China; 2Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing 210009, Jiangsu Province, People’s Republic of China *These authors contributed equally to this work Abstract: Hypoxia is one of the marked features of malignant tumors, which is associated with several adaptation changes in the microenvironment of tumor cells. Therefore, targeting tumor hypoxia is a research hotspot for cancer therapy. In this review, we summarize the developing chemotherapeutic drugs for targeting hypoxia, including quinones, nitroaromatic/nitroimidazole, N-oxides, and transition metal complexes. In addition, redox-responsive bonds, such as nitroimidazole groups, azo-groups, and disulfide bonds, are frequently used in drug delivery systems for targeting the redox environment of tumors. Both hypoxia-activated prodrugs and redox-responsive drug delivery nanocarriers have significant effects on targeting tumor hypoxia for cancer therapy. Hypoxia-activated prodrugs are commonly used in clinical trials with favorable prospects, while redox-responsive nanocarriers are currently at the experimental stage. Keywords: antitumor drugs, hypoxia, nanoparticles, redox-sensitive, tumor therapy Zeng YMa JZhan YXu XZeng QLiang JChen XDove Medical PressarticleAnti-tumor drugsHypoxiaNanoparticlesRedox-sensitiveTumor therapyMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 13, Pp 6551-6574 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Anti-tumor drugs Hypoxia Nanoparticles Redox-sensitive Tumor therapy Medicine (General) R5-920
spellingShingle	Anti-tumor drugs Hypoxia Nanoparticles Redox-sensitive Tumor therapy Medicine (General) R5-920 Zeng Y Ma J Zhan Y Xu X Zeng Q Liang J Chen X Hypoxia-activated prodrugs and redox-responsive nanocarriers
description	Yun Zeng,1,* Jingwen Ma,2,* Yonghua Zhan,1 Xinyi Xu,1 Qi Zeng,1 Jimin Liang,1 Xueli Chen1 1Engineering Research Center of Molecular and Neuro Imaging of the Ministry of Education, School of Life Science and Technology, Xidian University, Xi’an 710071, Shaanxi Province, People’s Republic of China; 2Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing 210009, Jiangsu Province, People’s Republic of China *These authors contributed equally to this work Abstract: Hypoxia is one of the marked features of malignant tumors, which is associated with several adaptation changes in the microenvironment of tumor cells. Therefore, targeting tumor hypoxia is a research hotspot for cancer therapy. In this review, we summarize the developing chemotherapeutic drugs for targeting hypoxia, including quinones, nitroaromatic/nitroimidazole, N-oxides, and transition metal complexes. In addition, redox-responsive bonds, such as nitroimidazole groups, azo-groups, and disulfide bonds, are frequently used in drug delivery systems for targeting the redox environment of tumors. Both hypoxia-activated prodrugs and redox-responsive drug delivery nanocarriers have significant effects on targeting tumor hypoxia for cancer therapy. Hypoxia-activated prodrugs are commonly used in clinical trials with favorable prospects, while redox-responsive nanocarriers are currently at the experimental stage. Keywords: antitumor drugs, hypoxia, nanoparticles, redox-sensitive, tumor therapy
format	article
author	Zeng Y Ma J Zhan Y Xu X Zeng Q Liang J Chen X
author_facet	Zeng Y Ma J Zhan Y Xu X Zeng Q Liang J Chen X
author_sort	Zeng Y
title	Hypoxia-activated prodrugs and redox-responsive nanocarriers
title_short	Hypoxia-activated prodrugs and redox-responsive nanocarriers
title_full	Hypoxia-activated prodrugs and redox-responsive nanocarriers
title_fullStr	Hypoxia-activated prodrugs and redox-responsive nanocarriers
title_full_unstemmed	Hypoxia-activated prodrugs and redox-responsive nanocarriers
title_sort	hypoxia-activated prodrugs and redox-responsive nanocarriers
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/13e8874b1c0449268f8e766f8935a70f
work_keys_str_mv	AT zengy hypoxiaactivatedprodrugsandredoxresponsivenanocarriers AT maj hypoxiaactivatedprodrugsandredoxresponsivenanocarriers AT zhany hypoxiaactivatedprodrugsandredoxresponsivenanocarriers AT xux hypoxiaactivatedprodrugsandredoxresponsivenanocarriers AT zengq hypoxiaactivatedprodrugsandredoxresponsivenanocarriers AT liangj hypoxiaactivatedprodrugsandredoxresponsivenanocarriers AT chenx hypoxiaactivatedprodrugsandredoxresponsivenanocarriers
_version_	1718400992641286144

Hypoxia-activated prodrugs and redox-responsive nanocarriers

Ejemplares similares